Embecta Corp. (EMBC)
11.95
+0.41
(+3.55%)
USD |
NASDAQ |
Dec 11, 16:00
11.96
+0.01
(+0.08%)
After-Hours: 20:00
Embecta EPS Diluted (Quarterly): 0.4485 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Becton, Dickinson & Co. | 1.717 |
| AIM ImmunoTech, Inc. | -1.569 |
| Perspective Therapeutics, Inc. | -0.3495 |
| Protalix Biotherapeutics, Inc. | 0.0291 |
| Armata Pharmaceuticals, Inc. | -0.7363 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 26.40M |
| Revenue (Quarterly) | 264.00M |
| Total Expenses (Quarterly) | 237.60M |
| Enterprise Value | 1.918B |
| Gross Profit Margin (Quarterly) | 59.09% |
| Profit Margin (Quarterly) | 10.00% |
| Earnings Yield | 13.62% |
| Operating Earnings Yield | 46.51% |
| Normalized Earnings Yield | 22.00 |